Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Weill Medical College of Cornell University
With
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed diagnosis of recurrent B cell non-Hodgkin's lymphoma or diagnosis of recurrent chronic lymphocytic leukemia
Patient has received at least one prior treatment with standard chemotherapy and at least one prior treatment with rituximab (negative HAHA test required if received prior humanized antibody treatment)
Patient has not received anti-cancer therapy within 28 days of treatment unless disease progression has been demonstrated and toxicities from prior therapy have resolved
Available tumor tissue (lymph node/mass, blood or bone marrow) for correlative analyses (paraffin or frozen, recent or archived)
Measurable disease as defined by a tumor mass \> 1.5 cm in one dimension or WBC \> 5,000 (CLL patients)
Age \> 18 years
Patient has KPS \> 50%
Absolute granulocyte count \> 1000 cells/mm3
Platelet count \> 50,000 cells/mm3
Creatinine \< 2.0 x ULN
Total bilirubin \< 2.0 x ULN
Patient agrees to use birth control if of reproductive potential
Patient has signed IRB-approved informed consent
You may not be if
Known central nervous system (CNS) involvement by lymphoma
Known HIV disease
Patient is pregnant or nursing
Patient is receiving other investigational drugs
Known serum human anti-human antibodies (HAHA)
Estimated life expectancy of \< 3 months
Clareo Health | Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies
